Literature DB >> 1517683

Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia.

T E Warkentin1, C P Hayward, C A Smith, P M Kelly, J G Kelton.   

Abstract

Heparin-induced thrombocytopenia is a common immune-mediated drug reaction that can be complicated by life-threatening arterial thrombosis. The diagnosis can be confirmed by demonstrating heparin-dependent release of radiolabeled serotonin from washed normal platelets in the presence of patient serum. However, certain serum samples from these patients produce 14C-serotonin release from some but not other normal donor platelets. We investigated this problem of donor platelet variability by studying the reactivities of 10 serum samples from patients with heparin-induced thrombocytopenia with platelets from 10 normal donors (100 serum and platelet combinations). We observed a marked variability in reactivity for patient serum and platelets from normal donors; this initially appeared random. However, closer examination indicated that the reactivities varied hierarchically. Because heparin-induced thrombocytopenia is caused by binding of heparin-dependent IgG to platelet Fc receptors, we examined whether platelet Fc receptor number or function explained the variability in platelet reactivity. We observed that platelet Fc receptor function, as measured by platelet release associated with heat-aggregated IgG, was highly correlated with platelet reactivity to heparin-induced thrombocytopenia serum samples. No significant correlation, however, was found between Fc receptor number and platelet response. Reaction of murine monoclonal antibodies that activate human platelets by means of the platelet Fc receptors was not predictive of platelet reactivity to heparin-induced thrombocytopenia serum.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517683

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  22 in total

Review 1.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 2.  Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants.

Authors:  Albrecht Leo; Susanne Winteroll
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 3.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Authors:  Theodore E Warkentin; Richard J Cook; Victor J Marder; Jo-Ann I Sheppard; Jane C Moore; Bengt I Eriksson; Andreas Greinacher; John G Kelton
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

5.  High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response.

Authors:  A Winder; Y Shoenfeld; R Hochman; G Keren; Y Levy; A Eldor
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

6.  Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay.

Authors:  Klara Železnik; Primož Rožman; Eva Kocjan; Elvira Maličev
Journal:  Blood Transfus       Date:  2020-10-09       Impact factor: 3.443

7.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08

Review 8.  Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.

Authors:  W N Patton; S B Duffull
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

9.  Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.

Authors:  Sixten Selleng; Kathleen Selleng; Sigrun Friesecke; Matthias Gründling; Sven-Olaf Kuhn; Ricarda Raschke; Olivia J Heidecke; Carsten Hinz; Gregor Hron; Theodore E Warkentin; Andreas Greinacher
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

10.  Repeated early hemofiltration filters clotting and heparin-induced thrombocytopenia in ICU.

Authors:  Sébastien Perbet; Thomas Godet; Aurélien Lebreton; Anne-Françoise Sapin; Jean-Michel Constantin
Journal:  J Clin Monit Comput       Date:  2014-06-11       Impact factor: 2.502

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.